Trial Profile
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Retifanlimab (Primary) ; Vobramitamab duocarmazine (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 23 Aug 2023 Protocol has been amended due to change in Treatment arm from 11 to 10
- 06 May 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 20 Apr 2023 Status changed from active, no longer recruiting to discontinued as per business decision.